Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

Alberto Borghetti; Andrea Giacomelli; Vanni Borghi; Arturo Ciccullo; Alex Dusina; Massimiliano Fabbiani; Stefano Rusconi; Maurizio Zazzi; Cristina Mussini; Simona Di Giambenedetto

doi:10.1093/ofid/ofab103

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

Alberto Borghetti, Andrea Giacomelli, Vanni Borghi, Arturo Ciccullo, Alex Dusina, Massimiliano Fabbiani, Stefano Rusconi, Maurizio Zazzi, Cristina Mussini, Simona Di Giambenedetto

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.

Lingua originale	English
pagine (da-a)	ofab103-ofab103
Rivista	Open Forum Infectious Diseases
Volume	8
DOI	https://doi.org/10.1093/ofid/ofab103
Stato di pubblicazione	Pubblicato - 2021

Keywords

HIV
dolutegravir
lamivudine
maintenance therapy
resistance-associated mutations

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1093/ofid/ofab103

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint

Entra nei temi di ricerca di 'Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice'. Insieme formano una fingerprint unica.

Cita questo

Borghetti, A., Giacomelli, A., Borghi, V., Ciccullo, A., Dusina, A., Fabbiani, M., Rusconi, S., Zazzi, M., Mussini, C., & Di Giambenedetto, S. (2021). Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice. Open Forum Infectious Diseases, 8, ofab103-ofab103. https://doi.org/10.1093/ofid/ofab103

@article{262e9671fce4461093301589d2f2b9ca,

title = "Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice",

abstract = "The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.",

keywords = "HIV, dolutegravir, lamivudine, maintenance therapy, resistance-associated mutations, HIV, dolutegravir, lamivudine, maintenance therapy, resistance-associated mutations",

author = "Alberto Borghetti and Andrea Giacomelli and Vanni Borghi and Arturo Ciccullo and Alex Dusina and Massimiliano Fabbiani and Stefano Rusconi and Maurizio Zazzi and Cristina Mussini and {Di Giambenedetto}, Simona",

year = "2021",

doi = "10.1093/ofid/ofab103",

language = "English",

volume = "8",

pages = "ofab103--ofab103",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

}

Borghetti, A, Giacomelli, A, Borghi, V, Ciccullo, A, Dusina, A, Fabbiani, M, Rusconi, S, Zazzi, M, Mussini, C & Di Giambenedetto, S 2021, 'Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice', Open Forum Infectious Diseases, vol. 8, pagg. ofab103-ofab103. https://doi.org/10.1093/ofid/ofab103

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice. / Borghetti, Alberto; Giacomelli, Andrea; Borghi, Vanni et al.
In: Open Forum Infectious Diseases, Vol. 8, 2021, pag. ofab103-ofab103.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice

AU - Borghetti, Alberto

AU - Giacomelli, Andrea

AU - Borghi, Vanni

AU - Ciccullo, Arturo

AU - Dusina, Alex

AU - Fabbiani, Massimiliano

AU - Rusconi, Stefano

AU - Zazzi, Maurizio

AU - Mussini, Cristina

AU - Di Giambenedetto, Simona

PY - 2021

Y1 - 2021

N2 - The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.

AB - The TANGO trial demonstrated the efficacy of lamivudine plus dolutegravir in virologically suppressed patients without previous virological failures (VFs). In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least 1 thymidine analog-associated mutation significantly increased the risk of VF.

KW - HIV

KW - dolutegravir

KW - lamivudine

KW - maintenance therapy

KW - resistance-associated mutations

KW - HIV

KW - dolutegravir

KW - lamivudine

KW - maintenance therapy

KW - resistance-associated mutations

UR - http://hdl.handle.net/10807/193227

U2 - 10.1093/ofid/ofab103

DO - 10.1093/ofid/ofab103

M3 - Article

SN - 2328-8957

VL - 8

SP - ofab103-ofab103

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

ER -

Borghetti A, Giacomelli A, Borghi V, Ciccullo A, Dusina A, Fabbiani M et al. Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice. Open Forum Infectious Diseases. 2021;8:ofab103-ofab103. doi: 10.1093/ofid/ofab103